AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more
AEON Biopharma, Inc. (AEON) - Net Assets
Latest net assets as of September 2025: $-19.87 Million USD
Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has net assets worth $-19.87 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.73 Million) and total liabilities ($28.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-19.87 Million |
| % of Total Assets | -227.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AEON Biopharma, Inc. - Net Assets Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual net assets of AEON Biopharma, Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-28.57 Million | +81.33% |
| 2023-12-31 | $-153.04 Million | +43.40% |
| 2022-12-31 | $-270.41 Million | -20.82% |
| 2021-12-31 | $-223.82 Million | -10.13% |
| 2020-12-31 | $-203.23 Million | -208.54% |
| 2019-12-31 | $-65.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AEON Biopharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9786400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | % |
| Other Components | $403.02 Million | % |
| Total Equity | $-28.57 Million | 100.00% |
AEON Biopharma, Inc. Competitors by Market Cap
The table below lists competitors of AEON Biopharma, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FIINU LS -10
F:LWW
|
$9.34 Million |
|
Feerum S.A.
WAR:FEE
|
$9.35 Million |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
$9.35 Million |
|
Horseshoe Metals Ltd
AU:HOR
|
$9.35 Million |
|
Catenon S.A
MC:COM
|
$9.34 Million |
|
Vimedimex Medi Pharma JSC
VN:VMD
|
$9.34 Million |
|
Pansar Bhd
KLSE:8419
|
$9.33 Million |
|
The Byke Hospitality Ltd
NSE:BYKE
|
$9.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AEON Biopharma, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -153,044,000 to -28,569,000, a change of 124,475,000.
- Net income of 42,005,000 contributed positively to equity growth.
- New share issuances of 147,000 increased equity.
- Other factors increased equity by 82,323,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $42.01 Million | +147.03% |
| Share Issuances | $147.00K | +0.51% |
| Other Changes | $82.32 Million | +288.15% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares AEON Biopharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-727.51 | $1.14 | x |
| 2020-12-31 | $-2273.18 | $1.14 | x |
| 2021-12-31 | $-133.99 | $1.14 | x |
| 2022-12-31 | $-149.08 | $1.14 | x |
| 2023-12-31 | $-1.99 | $1.14 | x |
| 2024-12-31 | $-49.60 | $1.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AEON Biopharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 5151.03% | 0.03x | 0.00x | $179.63 Million |
| 2020 | 0.00% | -1307.11% | 0.12x | 0.00x | $-12.09 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.14 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.81 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-369.33 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $44.86 Million |
Industry Comparison
This section compares AEON Biopharma, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AEON Biopharma, Inc. (AEON) | $-19.87 Million | 0.00% | N/A | $9.34 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |